US Patent

US8008264 — 1′-substituted carba-nucleoside analogs for antiviral treatment

Composition of Matter · Assigned to Gilead Sciences Inc · Expires 2029-09-06 · 3y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel nucleoside compounds and their derivatives for treating Flaviviridae virus infections, particularly hepatitis C.

USPTO Abstract

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Drugs covered by this patent

Patent Metadata

Patent number
US8008264
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-09-06
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.